



Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic–tandem mass spectrometric method

Abhishek Srivastava, David Waterhouse, Alison Ardrey, Stephen A. Ward*

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom

ARTICLE INFO

Article history:

Received 7 January 2012
Received in revised form 21 May 2012
Accepted 23 May 2012
Available online 1 June 2012

Keywords:

Rifampicin
LC–MS/MS
Human plasma
Cerebrospinal fluid
Validation
Quantitative assay

ABSTRACT

A highly sensitive and rapid liquid chromatography tandem mass spectrometry (LC–MS/MS) method has been developed to measure the levels of the antitubercular drug rifampicin (RIF) in human plasma and cerebrospinal fluid (CSF). The analyte and internal standard (IS) were isolated from plasma and CSF by a simple organic solvent based precipitation of proteins followed by centrifugation. Detection was carried out by electrospray positive ionization mass spectrometry in the multiple-reaction monitoring (MRM) mode. The assay was linear in the concentration range 25–6400 ng/mL with intra- and inter-day precision of <7% and <8%, respectively. The validated method was applied to the study of RIF pharmacokinetics in human CSF and plasma over 25 h period after a 10 mg/kg oral dose.

© 2012 Elsevier B.V. Open access under [CC BY license](http://creativecommons.org/licenses/by/3.0/).

1. Introduction

Tuberculosis (TB) is one of the most important human bacterial diseases caused by mycobacterium tuberculosis (MTB) commonly affecting the lungs [1]. It is an aggressive disease with one third of the World's population reportedly being infected with MTB [1,2]. It is more common in developing countries, with more than half of the reported cases occurring in Asia [1]. Rifamycins are a group of complex, macrocyclic antibiotics produced by *Amycolatopsis mediterranei* that are one of the most important first line anti-TB drugs [3]. Among them RIF has been used for the treatment of TB, leprosy [4,5], some types of osteomyelitis and endocarditis [6]. The drug is most regularly deployed in the cocktail of drugs used as first-line treatment for TB. RIF inhibits DNA-dependent RNA polymerase in bacterial cells. Although the drug has been in use for many decades there are still questions about the appropriateness of dosage regimes in specific patient groups such as those co-infected with HIV and young children. In order to address these questions there is a need for a suitably selective and sensitive analytical method that is capable of measuring the drug in biological fluids. Several analytical methods are already available for the deter-

mination of RIF in biological fluids and pharmaceutical dosage forms, including methods based on HPTLC [7], HPLC [8–16], HPLC following SPE [17] or SBSE [18], UPLC [19], LC–MS/MS [20–23] and MALDI–TOF [24]. In all cases there are some drawbacks associated with existing methods making them unsuitable for satisfactory quantitative analysis in studies that have been designed and implemented as part of an integrated TB clinical pharmacology programme in the Liverpool School of Tropical Medicine. In some cases there is no inclusion of an IS which compromises the robustness of the method [8,15,17], some assays need relatively large volumes of sample and/or lacked sensitivity which limits their usefulness in pediatric studies where sample volumes are severely constrained [12–14] and other assays involve complex or very long extraction procedures thereby compromising throughput [10,11,13,16]. The aim of the work presented here was to develop a rapid and sensitive LC–MS/MS method for the quantification of RIF in human plasma and CSF samples. We have established an exacting, sensitive and reproducible analytical method requiring only a small sample volume and involving quick sample processing as key benefits of this assay for the quantitative analysis of RIF. The developed method was validated according to the FDA guidelines [25].

2. Materials and methods

2.1. Solvents and chemicals

RIF (C₄₇H₆₄N₄O₁₂; MW 822.94) and rifapentine (RPT; C₁₅H₂₄O₅; MW 264.36) were purchased from Sigma–Aldrich (Poole, Dorset,

Abbreviations: CSF, cerebrospinal fluid; MTB, mycobacterium tuberculosis; RPT, rifapentine; RIF, rifampicin; TB, tuberculosis.

* Corresponding author. Tel.: +44 151 705 3286; fax: +44 151 705 3371.

E-mail addresses: abhishek.srivastava@liverpool.ac.uk (A. Srivastava), saward@liverpool.ac.uk (S.A. Ward).

2.6.1. Selectivity

The selectivity of the method was evaluated by analysing six independent drug-free plasma samples with reference to potential interferences from isobaric endogenous and environmental constituents.

2.6.2. Calibration curve

Calibration curves were generated to confirm the relationship between the peak area ratios and the concentration of RIF in the standard samples. Fresh CS were extracted and assayed as described above on three different days and in duplicate. Calibration curves for RIF were represented by the plots of the peak-area ratio (RIF/RPT) versus the nominal concentration of the RIF in CS. The line of best fit was generated using $1/\text{concentration}^2$ weighted quadratic regression as the mathematical model of best fit. RIF concentrations in QC samples, recovery samples, stability samples and experimental CSF/plasma pharmacokinetic samples were calculated from the resulting area ratio and the regression equation of the calibration curve.

2.6.3. Accuracy and precision

Intra-day accuracy and precision were evaluated by analysis of QCs at four levels (LLOQ, LQC, MQC and HQC; $n=6$ at each level) on the same day. Inter-day precision and the accuracy were determined by analysing four QC levels on 3 separate days ($n=6$ at each level) along with three separate standard curves done in duplicates. The accuracy of an analytical method describes how close the mean test results obtained by the method are to the nominal concentration of the analyte. Accuracy was calculated by the following equation, expressed as a percentage:

$$\text{Accuracy (\%)} = \frac{\text{mean observed concentration}}{\text{nominal concentration}} \times 100$$

The precision was expressed by coefficient of variation (CV). The CV % indicates the variability around the mean in relation to the size of the mean, and is defined as:

$$\text{CV (\%)} = \frac{\text{standard deviation}}{\text{mean observed concentration}} \times 100$$

2.6.4. Limit of detection and limit of quantification

The lower limit of quantification (LLOQ) was determined based on the criterion that the analyte response at LLOQ is five times baseline noise and it is within the acceptable limit of accuracy and precision. Higher limit of quantification (HLOQ) was assigned to the highest point in the standard curve. Intra-day and inter-day accuracy and precision for HLOQ and LLOQ samples were evaluated in the same manner as the QC samples (Section 2.6.3). The LOD was determined as the lowest concentration which gives a signal-to-noise ratio of three for the analytes.

2.6.5. Carryover test

Carry over tests were performed by injection of blank plasma sample directly after the highest point in calibration curve.

2.6.6. Stability

Autosampler, freeze–thaw and plasma heat-inactivation stability of RIF was determined at low, medium and high QC concentrations. To determine the impact of plasma heat inactivation or freeze–thaw cycles on RIF concentration, samples were heat inactivated for 40 min at 58 °C or underwent 3 freeze (–80 °C) thaw (room temperature) cycles. Following sample treatment/storage conditions, the RIF concentrations were analyzed in triplicates and compared to the control sample that had been stored at –80 °C. Autosampler stability of extracted samples was determined by

comparing RIF concentration in freshly prepared samples and samples kept in autosampler at 4 °C for 24 h.

2.6.7. % recovery and matrix effect

Recovery was determined by comparing the area under the curve (AUC) of extracted QC samples (LQC, MQC and HQC) with direct injection of extracted blank plasma spiked with the same nominal concentration of RIF as in the QC samples. This should highlight any loss in signal due to the extraction process. IS recovery was determined for a single concentration of 250 ng/mL.

Matrix effects were evaluated using heat-treated and untreated blank human plasma from six different donors using post-column infusion experiments as described by Hanpithakpong et al. [26]. Post column infusion provides a visual assessment of the effect of the sample matrix over an entire chromatographic run to ensure that no interfering peaks are found in the elution windows of analytes and IS. The syringe pump of the MS was setup containing a mixture of 250 ng/mL RIF and RPT in methanol. This solution was infused directly through a T-connector in to the MS at a constant flow rate of 10 $\mu\text{L}/\text{min}$, whilst the blank plasma extract was injected via the autosampler. The chromatograms produced were compared to an injection of mobile phase. Any ion suppression could be seen as a change in deviation in the response of the infused analyte that was greater than the underlying system noise.

Moreover, estimation of the matrix effects was also obtained by comparing the peak area for samples spiked in elution solution with extracted blank matrix spiked with the same nominal concentration of RIF.

2.7. Data analysis

LC–MS data acquisition and processing was performed by LC Quan™ software. Standard curves for quantification of RIF were constructed using a $1/\text{concentration}^2$ weighted quadratic regression of the peak area ratio versus RIF concentration. Unknown and QC sample concentrations were back-calculated from the standard curves.

3. Results and discussion

3.1. Detection and chromatography

Fig. 2 shows the typical chromatograms of a blank human plasma sample (A), a spiked plasma sample with RIF (5.0 ng/mL, LLOQ) and IS (250.0 ng/mL) (B), a plasma sample from a patient 25 h after a 10 mg/kg oral dose of RIF (C) and a CSF sample from a patient receiving a 10 mg/kg daily oral dose of RIF (D). The retention times for RIF and IS were 2.1 and 2.8 min, respectively.

3.2. Method validation

3.2.1. Selectivity

The method was found to have high selectivity for the analytes, since no interfering peaks from endogenous compounds were observed at the retention time for RIF or RPT in any of the six independent blank plasma extracts evaluated (Fig. 2A).

3.2.2. Calibration curves

Calibration curves for RIF in human plasma and CSF were fitted by weighted $1/\text{concentration}^2$ quadratic regression, with the r^2 values of >0.99 for all curves generated during the validation and pharmacokinetic plasma analysis. The calibration curve accuracy for plasma is presented in Table 1 demonstrating that measured




Fig. 2. Representative MRM chromatograms of RIF (I) and RPT (II, IS) in: (A) a blank human plasma sample; (B) a blank human plasma sample spiked with RIF at the LLOQ of 25 ng/mL; (C) patient plasma sample 25 h after an oral dose of 10 mg/kg (RIF concentration; 31 ng/mL); (D) CSF sample from a patient receiving a 10 mg/kg daily oral dose of RIF (RIF concentration; 41.83 ng/mL). Sample preparation for 100 μ l of (B)–(D) was performed using 300 μ l of 50/50 ACN/methanol (including 250 ng/mL IS), whereas IS was not included in case of (A).

concentration is within $\pm 15\%$ of the actual concentration point (20% for the lowest point on the standard curve, the LLOQ). Results were calculated using peak area ratios. (Calibration curve data for CSF not shown)

Table 1
Analysis of plasma CS.

	Nominal conc. (ng/mL)	Mean conc. ^a (ng/mL)	CV (%)	Accuracy (%)
CS-1	25.00	24.48 \pm 2.0	8.15	97.91
CS-2	50.00	49.42 \pm 3.8	7.68	98.83
CS-3	200.00	198.65 \pm 14.27	7.19	99.33
CS-4	400.00	426.72 \pm 9.44	2.21	106.68
CS-5	800.00	793.48 \pm 78.86	9.94	99.19
CS-6	1600.00	1550.05 \pm 76.84	4.96	96.88
CS-7	3200.00	3250.46 \pm 227.62	7.00	101.58
CS-8	6400.00	6377.16 \pm 205.98	3.23	99.64

^a Data represent the mean \pm S.D of six observations.

3.2.3. Accuracy and precision

A detailed summary of the intra-day and inter-day precision and accuracy data generated for the assay validation is presented in Table 2. Inter-assay variability was expressed as the accuracy and precision of the mean QC concentrations (LLOQ, LQC, MQC, and HQC) of three separate assays. Intra-assay variability was determined as the accuracy and precision of the six individual QC concentrations within one assay. The inter- and intra-assay accuracy and precision was $<10\%$ for all QC concentrations, which was within the general assay acceptability criteria for QC samples according to FDA guidelines [25].

3.2.4. Limit of detection and limit of quantification

LOD was defined as the lowest concentration that produced a peak distinguishable from background noise (minimum ratio of 3:1). The approximate LOD was 2.5 ng/mL. The LLOQ has been accepted as the lowest points on the standard curve with a relative standard deviation of less than 20% and signal to noise ratio of 5:1. Results at lowest concentration studies (25 ng/mL) met the criteria for the LLOQ (Table 2). The method was found to be sufficiently sensitive for the determination of RIF in human plasma samples and CSF. The HLOQ has been accepted as the highest points on the standard curve with a relative standard deviation of less than 15% [25].

3.2.5. Carryover test

A critical issue with the analysis of many drugs is their tendency to get absorbed by reversed phase octadecyl-based chromatographic packing materials, resulting in the memory effect. However in this analysis no quantifiable carryover effect was obtained when a series of blank (plasma) solutions were injected immediately following the highest calibration standard.

3.2.6. Stability studies

The results of autosampler, freeze–thaw and heat-inactivation stability are presented in Table 3. Determination of RIF stability following three freeze–thaw cycles showed that for all QC samples there was a minor change in the RIF concentration. In contrast heat-inactivation showed major impact on the RIF concentrations measured for LQC (20.9%) and MQC (22.4%). However, HQC only showed a difference of 5.4% from initial concentration.

3.2.7. % recovery and matrix effect

Percentage recovery of RIF was measured by dividing the AUC values of extracted QC samples with direct injection of solution containing the same nominal concentration of compounds as the QC samples in extracted blank plasma. RIF recovery from plasma spiked with 75, 600, and 4800 ng/mL of RIF was 92.5 ± 2.17 , 93.2 ± 3.04 and 94.0 ± 2.70 , respectively ($n=6$). IS recovery at 250 ng/mL of RPT was 96.93 ± 2.39 .

Post-column infusion experiments confirmed the absence of regions with severe matrix effects (i.e. no sharp drops or increases in the response) for heat-treated and untreated blank human plasma extracted with the developed method (Fig. 3). Moreover, no suppression/enhancement for RIF could be detected when compound in neat injection solvent was compared with compound in extracted blank biological matrix.

3.2.8. Analysis of clinical samples

This method has been used for the measurement of RIF concentration in patient plasma and CSF samples (Table 5). Plasma-concentration data was analyzed by non-compartmental analysis using the Kinetica software package (Thermo Electron Corporation, UK) to obtain pharmacokinetic parameters (Table 4) including area under the curve (AUC_{0-t}) with extrapolation to

Table 2
Intra- and inter-day precision and accuracy data for assays of RIF in human plasma.

	Inter-day (n = 18)			Intra-day (n = 6)		
	Mean conc. ^a (ng/mL)	CV %	Accuracy %	Mean conc. (ng/mL)	CV %	Accuracy %
LLOQ (25 ng/mL)	23.23 ± 1.34	5.78	92.93	24.64 ± 1.51	6.16	98.58
LQC (75 ng/mL)	79.07 ± 6.13	7.75	105.43	82.59 ± 1.52	1.85	110.12
MQC (600 ng/mL)	641.33 ± 37.74	5.88	106.89	649.10 ± 16.81	2.59	108.18
HQC (4800 ng/mL)	5156.19 ± 268.85	5.21	107.42	4846.14 ± 109.91	2.27	100.96
HLOQ (6400 ng/mL)	6610.76 ± 223.44	3.38	103.29	6590 ± 372.57	5.65	102.98

^a The inter- and intra-assay data represent the mean ± S.D. of 18 and 6 observations, respectively.

infinity ($AUC_{0-\infty}$) and apparent elimination half-life ($t_{1/2}$) values. Maximum plasma concentration (C_{max}), the time-to-maximum concentration (T_{max}) values were obtained by visual inspection of the plasma concentration–time profile.




Fig. 3. MRM chromatograms obtained after injection of extracted (A) heat-treated and (B) untreated blank human plasma during post column infusion of RIF (I) and RPT (II). A mixture containing 250 ng/mL RIF and RPT in methanol was infused directly by syringe pump through a T-connector in to the MS at a constant flow rate of 10 μ l/min, whilst the blank plasma extract was injected via the autosampler.

Table 3
Stability of RIF in extracted sample and human plasma.^a

Treatment	LQC	MQC	HQC
Extracted sample/autosampler	4.0	–2.5	–0.8
Plasma/heat- inactivation	20.9	22.4	5.4
Plasma/3 \times freeze–thaw	–5.3	2.0	4.6

^a Data represented as % difference from initial sample.

Table 4
The main pharmacokinetic parameters of RIF in human plasma after an oral dose of 10 mg/kg.

Parameter	Values ^a
C_{max} (ng/mL)	3769
T_{max} (h)	4.0
$t_{1/2}$ (h)	2.8
AUC_{0-t} (ng h/mL)	27822.9
$AUC_{0-\infty}$ (ng h/mL)	27948.8

^a Data presented here is from one patient only.

Table 5
Quantification of RIF in human CSF after an oral dose of 10 mg/kg/day.

Sample ID	RIF concentration (ng/mL)
Patient 1 day 0	BLQ ^a
Patient 1 day 3	28.78
Patient 1 day 6	39.49
Patient 1 day 27	30.62
Patient 1 day 62	41.83
Patient 1 day 83	25.59
Patient 2 day 0	BLQ
Patient 2 day 55	96.89
Patient 2 day 83	268.84

^a BLQ, below limit of quantification.

4. Conclusion

An LC/ESI–MS/MS method was developed and validated for the determination of RIF in human plasma. The sample pre-treatment was a single-step liquid–liquid extraction procedure without any requirement for a drying step for sample concentration. Usually drying and reconstitution step is used to obtain lower sensitivity but the present method directly gives sensitivity as low as 25 ng/mL, further we can still go lower by adding drying and reconstitution step to the current method. This assay requires only a small volume of plasma (100 μ l). This may be of particular advantage for pediatric studies where children can only provide small volumes of blood, and when studying RIF concentrations in the CSF where sample volumes are limited. MTB is generally not present in large amounts in human plasma; however, the potential of HIV and/or hepatitis co-infection means that plasma samples need to be heat inactivated (58 $^{\circ}$ C, 40 min), however, data shown here indicate that the process of heat-inactivation significantly affects the size of the RIF signal. Therefore, we recommend the omission of heat inactivation where possible.

In conclusion, method validation following FDA guideline indicated that the developed method had high sensitivity with an LLOQ of 25 ng/mL, high recovery (>90%), reliability, specificity and excellent efficiency with a total running time of 6.0 min per sample, which is important for large batches of samples. The sensitive, simple and rapid LC/MS/MS assay is suitable for pharmacokinetic, bioavailability or bioequivalence studies of RIF in human subjects. This method has been successfully applied to analyze RIF concentrations in human plasma and CSF.

Acknowledgement

This work received financial support from the Wellcome Trust as part of the LOTLink initiative (SAW, AA, DW).

References

- [1] T.R. Frieden, T.R. Sterling, S.S. Munsiff, C.J. Watt, C. Dye, Tuberculosis, *Lancet* 362 (2003) 887–899.
- [2] S.H.E. Kaufmann, Is the development of a new tuberculosis vaccine possible? *Nat. Med.* 6 (2000) 955–960.
- [3] H.M. Blumberg, W.J. Burman, R.E. Chaisson, C.L. Daley, S.C. Etkind, L.N. Friedman, P. Fujiwara, M. Grzemska, P.C. Hopewell, M.D. Iseman, R.M. Jasmer, V. Koppaka, R.I. Menzies, R.J. O'Brien, R.R. Reves, L.B. Reichman, P.M. Simone, J.R. Starke, A.A. Vernon, American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis, *Am. J. Respir. Crit. Care Med.* 167 (2003) 603–662.
- [4] R.J.W. Rees, J.M.H. Pearson, M.F.R. Waters, Experimental and clinical studies on rifampicin in treatment of leprosy, *Br. Med. J.* 1 (1970) 89–92.
- [5] M.I. Bakker, M. Hatta, A. Kwenang, B.H. Van Benthem, S.M. Van Beers, P.R. Klatser, L. Oskam, Prevention of leprosy using rifampicin as chemoprophylaxis, *Am. J. Trop. Med. Hyg.* 72 (2005) 443–448.
- [6] J. Perliroth, M. Kuo, J. Tan, A.S. Bayer, L.G. Miller, Adjunctive use of rifampin for the treatment of *Staphylococcus aureus* infections: a systematic review of the literature, *Arch. Intern. Med.* 168 (2008) 805–819.
- [7] N. Udupa, P. Goyal, S. Agarwal, S. Venkatesh, S. Pandey, Simultaneous HPTLC determination of rifampicin and isoniazid in rat plasma, *Indian J. Pharm. Sci.* 65 (2003) 414–416.
- [8] I. Calleja, M.J. Blanco-Prieto, N. Ruz, M.J. Renedo, M.C. Dios-Viéitez, High-performance liquid-chromatographic determination of rifampicin in plasma and tissues, *J. Chromatogr. A* 1031 (2004) 289–294.
- [9] M.Y. Khuhawar, F.M.A. Rind, Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 766 (2002) 357–363.
- [10] E. Calleri, E. De Lorenzi, S. Furlanetto, G. Massolini, G. Caccialanza, Validation of a RP–LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation, *J. Pharm. Biomed. Anal.* 29 (2002) 1089–1096.
- [11] B. Mohan, N. Sharda, S. Singh, Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin, *J. Pharm. Biomed. Anal.* 31 (2003) 607–612.
- [12] A. Walubo, P. Smith, P.I. Folb, Comprehensive assay for pyrazinamide, rifampicin and isoniazid with its hydrazine metabolites in human plasma by column liquid chromatography, *J. Chromatogr. B Biomed. Sci. Appl.* 658 (1994) 391–396.
- [13] J. Woo, C.L. Wong, R. Teoh, K. Chan, Liquid chromatographic assay for the simultaneous determination of pyrazinamide and rifampicin in serum samples from patients with tuberculosis meningitis, *J. Chromatogr. B: Biomed. Sci. Appl.* 420 (1987) 73–80.
- [14] M. Ishii, H. Ogata, Determination of rifampicin and its main metabolites in human plasma by high-performance liquid chromatography, *J. Chromatogr. B: Biomed. Sci. Appl.* 426 (1988) 412–416.
- [15] H.I. Seifart, P.B. Kruger, D.P. Parkin, P.P. van Jaarsveld, P.R. Donald, Therapeutic monitoring of antituberculosis drugs by direct in-line extraction on a high-performance liquid chromatography system, *J. Chromatogr. Biomed. Appl.* 619 (1993) 285–290.
- [16] B. Ratti, R.R. Parenti, A. Toselli, L.F. Zerilli, Quantitative assay of rifampicin and its main metabolite 25-desacetyl-rifampicin in human plasma by reversed-phase high-performance liquid chromatography, *J. Chromatogr. B: Biomed. Sci. Appl.* 225 (1981) 526–531.
- [17] P.J. Smith, J.v. Dyk, A. Fredericks, Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma, *Int. J. Tuberc. Lung Dis.* 3 (1999) S325–S328.
- [18] M.S. Balbão, C. Bertucci, M.M. Bergamaschi, R.H.C. Queiroz, W.R. Malfará, S.A.C. Dreossi, L. de Paula Mello, M.E.C. Queiroz, Rifampicin determination in plasma by stir bar-sorptive extraction and liquid chromatography, *J. Pharm. Biomed. Anal.* 51 (2010) 1078–1083.
- [19] E. Gikas, F.N. Bazoti, P. Fanourgiakis, E. Perivolioti, A. Roussidis, A. Skoutelis, A. Tsarbobopoulos, Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: application to a pharmacokinetic study, *J. Pharm. Biomed. Anal.* 51 (2010) 901–906.
- [20] R.C. Hartkoorn, S. Khoo, D.J. Back, J.F. Tjia, C.J. Waitt, M. Chaponda, G. Davies, A. Ardrey, S. Ashleigh, S.A. Ward, A rapid and sensitive HPLC–MS method for the detection of plasma and cellular rifampicin, *J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci.* 857 (2007) 76–82.
- [21] W.A. Korfmacher, J. Bloom, M.I. Churchwell, T.A. Getek, E.B. Hansen Jr., C.L. Holder, K.T. McManus, Characterization of three rifamycins via electrospray mass spectrometry and HPLC–thermospray mass spectrometry, *J. Chromatogr. Sci.* 31 (1993) 498–501.
- [22] L. Baietto, A. D'Avolio, F.G. De Rosa, S. Garazzino, M. Michelazzo, G. Ventimiglia, M. Siccardi, M. Simiele, M. Sciandra, G. Di Perri, Development and validation of a simultaneous extraction procedure for HPLC–MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma, *Anal. Bioanal. Chem.* 396 (2010) 791–798.
- [23] F. de Velde, J.W.C. Alffenaar, A.M.A. Wessels, B. Greijdanus, D.R.A. Uges, Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography–tandem mass spectrometry, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 877 (2009) 1771–1777.
- [24] S. Notari, C. Mancone, M. Sergi, F. Gullotta, N. Bevilacqua, M. Tempestilli, R. Urso, F.N. Lauria, L.P. Pucillo, M. Tripodi, P. Ascenzi, Determination of antituberculosis drug concentration in human plasma by MALDI–TOF/TOF, *IUBMB Life* 62 (2010) 387–393.
- [25] Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, 2001.
- [26] W. Hanpithakpong, B. Kamanikom, A.M. Dondorp, P. Singhasivanon, N.J. White, N.P.J. Day, N. Lindegardh, A liquid chromatographic–tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma, *J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci.* 876 (2008) 61–68.